GSK Type 1 Diabetes Drug Does Not Make It in Phase III Clinical Trials

A Type 1 diabetes drug developed by London-based GlaxoSmithKline and Cambridge, Massachusetts-based Tolerx, was not successful in the phase III clinical trials.

Explaining their commitment to the clinical development of type 1 diabetes drug, Jackie Parkin, GSK's medicines development leader, said, "Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward."

Source: Medindia